Valeant Pharmaceuticals International, Inc. announced the launch of SILIQ™ (brodalumab) Injection during the Summer American Academy of Dermatology (AAD) meeting taking place in New York from July 27-30, 2017. SILIQ, a monoclonal antibody that targets the

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In